Scientific Interchange & Workshop
Sponsored by Daiichi Sankyo. Content independently developed by OncLive®.
Sponsored in part by Servier Pharmaceuticals. Content independently developed by OncLive.
Funding from Daiichi Sankyo; Content Developed Independently by OncLive.
Funding from Daiichi Sankyo; Content Developed Independently by OncLive.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5